

Kings Arms Yard VCT PLC

AGM June 2023

Results for the year to 31 December 2022



AGENDA

Financial summary

Background

Performance data

Highlights in the year

Investment portfolio

Realisations

Investment strategy

ESG & responsible investing

Prospects, Q1 results and shareholder events

FINANCIAL SUMMARY TO DEC 2022

20.95p

Net asset value (NAV)
per share as at
31 December 2022

94.43p

Total shareholder value
as at 31 December 2022

0.9%


Shareholder return for
the year ended 31
December 2022

2.30p


Tax-free dividends
per share paid
during the year

BACKGROUND

- Continued global macro and geo-political uncertainties
- Inflationary environment
- Prospect of further interest rate rises
- A small return for the year due to challenging market conditions
- Portfolio focus on mission critical products and services is designed to provide resilience
- Strong Q1 performance



PERFORMANCE DATA




HIGHLIGHTS IN THE YEAR

	2021	2022	Notes
Fundraising	£8.0m	£12.9m	2022 fundraising included allotments under two offers: 2021/22 & 2022/23 Top Up Offers
Exits	£26.8m	£8.3m	Including MyMeds&Me, Phrasee and Credit Kudos
Investment rate	£6.6m	£16.7m	£9.9m in 15 new companies and £6.8m into existing portfolio
Share buybacks	£1.7m	£2.3m	
Dividends	£10.3m	£10.8m	Includes £5m special dividend paid July 2022
Performance Incentive Fee	£1.0m	-	

KEY VALUE DRIVERS IN THE YEAR

	2022	Notes
MyMeds&Me	£2.7m	Sold for 3.3x cost
Celoxica Holdings PLC	£1.2m	Strong trading
Black Swan	(£1.0m)	Slower growth
uMotif	(£0.8m)	Slower growth
Other – write ups	£3.6m	Including: Solidatus, Convertr Media and Gravitee Topco (T/A Gravitee.io)
Other – write downs	(£3.5m)	Including: Sift, Oviva and Elliptic
TOTAL	£2.2m	


PORTFOLIO ANALYSIS



Portfolio of 65 companies employing over 4,600 people predominantly in the UK


PORTFOLIO ANALYSIS

Stage of investment






- Early stage (revenue less than £1 million) 12% (11%)
- Growth (revenue between £1 million and £5 million) 18% (24%)
- Scale up (revenue over £5 million) 70% (65%)

No. of employees



- Up to 20 6% (3%)
- 21 - 50 12% (28%)
- 51 - 100 24% (18%)
- 101+ 44% (35%)
- Renewable energy* 14% (16%)

TOP 3 ACCOUNT FOR 24.2% OF THE NAV AT DEC 2022

		Investment date	Cost £000	Book value £000	Revenue growth	Employee growth
	European specialist pharmaceutical company focussed on children's medicines	2012	2,259	9,672	Pre revenue to £15m p.a	4 to 64
	Uses the latest advances in big data analytics and artificial intelligence to help its financial services and government customers detect financial crime	2017	1,329	9,126	>50x	30 to c.600
	The leading cloud encryption platform ensuring data security for email, data transfer and collaboration environments	2014	1,644	6,361	>20x	23 to c.300
			£5.2m	£25.2m		

NEW INVESTMENTS

toqio

£1.5m

Provider of
embedded FinTech
solutions

Peppy

£1.4m

An employee digital
healthcare platform
for underserved
health and wellness
areas

 **perchpeek**

£1.0m

A digital relocation
platform


PeakData

£1.0m

Provides insights
and analytics to
pharmaceutical
companies about
therapeutic areas

csgenetics
SINGLE-CELL AT SCALE SINGLE-CELL AT SPEED

£0.8m

GX Molecular (T/A
CS Genetics)
develops single-cell
sequencing
solutions

NEW INVESTMENT: TOQIO

1

Toqio Fintech Holdings
is a provider of
embedded FinTech
solutions



- Toqio allows any business to launch embedded finance within days without building and managing complex software
- £7.4m invested by Albion VCTs, of which £1.5m from KAY
- Funding will be used for product development and expansion

NEW INVESTMENT: PEPPY HEALTH

2

Employee digital
healthcare platform
for underserved
health and wellness
areas



- Launched in 2018 with menopause support as an employee benefit – the first in the world
- £8m invested by Albion VCTs, of which £1.4m from KAY
- Funding will be used to accelerate expansion in the US

FOLLOW-ONS



£1.1m

TransFICC is a provider of a connectivity solution, connecting financial institutions with trading venues via a single API



£0.9m

Healios is a provider of an online platform delivering family centric psychological care primarily to children and adolescents



£0.8m

Runa Network (previously WeGift) is a cloud platform and infrastructure that enables corporates to issue digital incentives and payouts



£0.7m

Gravitee Topco (T/A Gravitee.io) is an API management platform

1

REALISATIONS: MYMEDS&ME

- Digital pharma SaaS platform that captures safety data directly from patients and healthcare professionals across multiple channels
- Acquired by Stanley Capital

£3.3m

Invested by Albion VCTs

3.4x

Cash on cash multiple

£4.9m

KAY VCT proceeds

REALISATIONS: PHRASEE

- An AI platform that generates optimised marketing campaigns
- Acquired by Capital D

£4.0m


Invested by Albion VCTs

3.5x

Cash on cash multiple

£2.3m

KAY VCT proceeds



INVESTMENT STRATEGY



Seed to Series B
(early stage
to growth)



Backing
Long-term
trends



Focus on
B2B



Target
software and
healthcare



ESG AND RESPONSIBLE INVESTING

Our commitment

- Devise an appropriate risk-return profile for our investments
- Deliver value to our investors
- Develop sustainable long-term strategies for our portfolio companies

Our process

- Integrates ESG principles at all stages of investment
- Measures the sustainability and societal impact of our investments

ESG AT ALBION

ENVIRONMENTAL

- Net Zero target by 2030
- Measuring carbon footprint with Plan A
- Purchased carbon removal permits for 2021/2022 emissions

SOCIAL

- Fair HQ score improvement (from 3.8 to 6.1 out of 10) within a year
- Mentoring for under-represented groups in VC
- Continued support for Whizz Kidz

GOVERNANCE

- ESG principles integrated across the full investment cycle
- Completion of 2022 ESG BSC portfolio reporting and targets set for 2023
- UN PRI score 2020/21: 3/5 stars
- Regular ESG updates for all stakeholders

PROSPECTS

- Ongoing uncertainties but balanced by strong individual portfolio company growth
- Well-balanced portfolio across target sectors and stage of maturity
- Focus on mission critical products and services, designed to provide resilience
- Limited exposure to discretionary consumer facing sectors
- Good level of cash to capitalise on new opportunities


Q1 RESULTS & EVENTS

- NAV at 31 March 2023 of 21.98p
 - Increase of 4.9% to the 31 December 2022 NAV
- Quantexa valuation has increased by £6.1m in the quarter
- Virtual AGMs
- Physical annual shareholder seminar
- First dividend of 0.52p per share paid on 28 April 2023
- Top three investments now account for 27.6% of NAV at 31 March 2023

Shareholder seminar details

 15 November 2023

 Royal College of Surgeons
Lincoln's Inn Fields, London

 To reserve a place, email
info@albion.capital

Thank you

This presentation is issued by Albion Capital Group LLP for information purposes only and is not to be regarded as an offer to buy or sell, or the solicitation to buy or sell shares in Kings Arms Yard VCT PLC. Any person considering an investment should seek advice from an authorised financial advisor.

Albion Capital Group LLP does not offer investment advice or make investment recommendations, nor offer tax advice and nothing in this presentation should be considered investment or tax advice.

The market value of, and the income derived from shares can fluctuate and there is no guarantee that the market price of shares will fully reflect their underlying net asset value. There can be no guarantee that the investment objectives will be met. There is no guarantee that target dividends will be paid.

Albion Capital Group LLP is authorised and regulated by the Financial Conduct Authority.